YUCAIPA, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Ingen Technologies, Inc. (OTC Bulletin Board: IGTG), a medical device manufacturer, announced today the signed distribution agreement with Progressive International Holding Co. LTD in Hong Kong to distribute Oxyview(R) in Taiwan, People's Republic of China, Japan and Korea. Please refer to the 8-K filing of this event.
Progressive International Holding Company (PIHK) (http://www.pgiholding.com) and its associate company, Progressive Group Inc (PGI), was founded in 1983 and is one of the major distributors of clinical diagnostic systems, medical devices and point of care products in Taiwan. To pursue the potential business opportunity in China and fully capitalize PGI's sales & marketing experience of more than twenty years, PGI established Progressive International Holding Company (PIHK) in Hong Kong in 2005. PIHK has tremendous synergy by utilizing the experience, expertise and connections of PGI in China and Taiwan to expand its product portfolio in patient oxygen gas flow monitoring devices in the China, Japan and Korea markets.
The distribution agreement calls for a monthly minimum of 10,000 Oxyview(R) units to be purchased by PIHK during a five year period. PIHK has submitted the application to the Chinese government agency known as SFDA for registration of the free sales certificate.
"Ingen looks forward to working closely with Progressive. Julian Yuan,
CEO of Progressive, visited our manufacturing facilities last year. Mr.
Yuan is CEO of Aviva Biosciences in San Diego, California
(http://www.avivabio.com), and has the resources to deliver Oxyview(R) to
the Asian markets. Our company is pleased to have the privilege of working
with Progressive International Holding Company," stated Scott Sand,
Chairman and CEO of Ingen Technologies.
For more information please visit: http://www.wallst.net/superstocks/superstocks_profile.asp?ticker=igtg
About Ingen Technologies, Inc.
Ingen Technologies, Inc., a Georgia Corporation, is a medical device
manufacturer, certified through the Department of Health Services, and a
publicly traded company trading under NASDAQ OTC: IGTG. The Company has
been in business since 1999. Ingen received FDA clearance last year and
offers products for the respiratory markets. The Oxyview(R) and OxyAlert(R)
are proprietary products that increase accuracy of medical care and prevent
unnecessary medical costs associated with today's healthcare industry.
Ingen owns a variety of intellectual biotech property, including several US
patent(s) and several Foreign Patent(s) either issued or pending in the US,
Japan, European Communities and People's Republic of China.
For more information, visit http://www.ingen-tech.com.
Contact: Scott R. Sand, C.E.O & Chairman
Ingen Technologies, Inc. -- Administrative Office
35193 Avenue "A", Suite-C
Yucaipa, California 92399
Phone: (909) 790-7180
Fax: (909) 795-6340
Member of the Better Business Bureau
Member of the Chamber of Commerce
Licensed Business in the City of Yucaipa
Certified Manufacturer with FDA/DHS
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
|SOURCE Ingen Technologies, Inc.|
Copyright©2008 PR Newswire.
All rights reserved